A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax in Subjects With Asthma

Trial Profile

A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax in Subjects With Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs Salbutamol (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 01 Apr 2015 According to Teva Pharmaceutical Industries media release, company receives FDA approval for ProAir RespiClick (albuterol sulfate) for treatment and prevention of bronchospasm and exercise induced bronchospasm in patients 12 age and over.
    • 21 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top